Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade F 3.72 0.54% 0.02
AGEN closed up 0.54 percent on Wednesday, April 26, 2017, on 52 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Apr 27

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical AGEN trend table...

Date Alert Name Type % Chg
Apr 26 Stochastic Reached Overbought Other 0.00%
Apr 26 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Apr 25 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.54%
Apr 24 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.33%
Apr 21 NR7 Range Contraction 5.68%
Apr 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.68%
Apr 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 8.14%
Apr 13 Stochastic Buy Signal Bullish 7.20%
Apr 11 NR7 Range Contraction 14.81%
Apr 11 Narrow Range Bar Range Contraction 14.81%

Older signals for AGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer’s disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company’s products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.49
52 Week Low 2.97
Average Volume 1,341,908
200-Day Moving Average 4.8554
50-Day Moving Average 3.8648
20-Day Moving Average 3.522
10-Day Moving Average 3.501
Average True Range 0.1732
ADX 17.14
+DI 26.03
-DI: 17.77
Chandelier Exit (Long, 3 ATRs) 3.5604
Chandelier Exit (Short, 3 ATRs) 3.7196
Upper Bollinger Band 3.9059
Lower Bollinger Band 3.1381
Percent B (%b) 0.76
Bandwidth 0.218001